Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
OPERATING ACTIVITIES
Net income (loss)	$ 45,799,000	$ (28,166,000)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Gain on sales	(125,500,000)	(49,904,000)
Impairment charges	25,979,000	80,887,000
Straight-line rents and expenses, net	(376,000)	(285,000)
Provision for doubtful accounts	1,070,000	606,000
Depreciation and amortization	19,088,000	30,978,000
Amortization of intangible lease liabilities, net	(595,000)	(807,000)
Expense relating to share-based compensation, net	1,608,000	2,509,000
Amortization of deferred financing costs	2,679,000	1,203,000
Changes in operating assets and liabilities, net of effects of acquisitions and dispositions:
Rents and other receivables	(15,232,000)	(862,000)
Prepaid expenses and other	(6,007,000)	(4,771,000)
Accounts payable and accrued liabilities	29,063,000	931,000
Net cash (used in) provided by operating activities	(22,424,000)	32,319,000
INVESTING ACTIVITIES
Expenditures for real estate improvements	(21,693,000)	(19,612,000)
Net proceeds from sales of real estate	699,337,000	104,497,000
Contributions to unconsolidated joint venture	(155,000)	(3,193,000)
Net cash provided by investing activities	677,489,000	81,692,000
FINANCING ACTIVITIES
Repayments under revolving credit facility	(70,000,000)	(188,000,000)
Advances under revolving credit facility	4,000,000	79,000,000
Repayment of term note	(300,000,000)	(100,000,000)
Proceeds (termination payment) related to interest rate swap	3,400,000	(503,000)
Mortgage proceeds	130,000,000	114,000,000
Mortgage repayments	(664,000)	(825,000)
Payments of debt financing costs	(3,807,000)	(3,261,000)
Noncontrolling interests:
Distributions to limited partners	(467,000)	(15,000)
Acquisition of joint venture minority interest share	(1,000,000)
Redemption of OP units	(966,000)	(8,000)
Common stock sales less issuance expenses, net		4,000
Preferred stock dividends	(8,064,000)	(8,064,000)
Distributions to common shareholders	(397,300,000)	(3,015,000)
Net cash used in financing activities	(644,868,000)	(110,687,000)
Net increase in cash, cash equivalents and restricted cash	10,197,000	3,324,000
Cash, cash equivalents and restricted cash at beginning of period	3,269,000	1,637,000
Cash, cash equivalents and restricted cash at end of period	13,466,000	4,961,000
Reconciliation to condensed consolidated balance sheets:
Cash and cash equivalents	2,062,000	4,731,000
Restricted cash	11,404,000	230,000
Cash, cash equivalents and restricted cash at end of period	$ 13,466,000	$ 4,961,000